Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Hemoglobinand Hematocrit: A Retrospective Analysis (SGLT-2 Inhibitors &Hemoconcentration)

Le résumé fourni par la source

Background: Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, such as Dapagliflozin and Empagliflozin, are a class of medications used in the management of type 2 diabetes mellitus and, more recently, heart failure and chronic kidney disease. An observed secondary effect of these drugs is an increase in hematocrit (Hct) and hemoglobin (Hb) levels. The mechanisms and clinical significance of these changes are still under investigation. Large cardiovascular outcome trials did not demonstrate a consistent signal for increased thromboembolic events; details on this subject will be mentioned in the discussion section. This study aims to analyze the effect of dapagliflozin and empagliflozin treatment on Hct and Hb in a cohort of 97 patients in our hospital.Methods: We conducted a retrospective analysis of a dataset containing information on 97 patients treated with either Dapagliflozin (n = 58) or Empagliflozin (n = 39). The dataset included baseline and 3–6-month follow-up measurements of Hct and Hb, along with demographic and clinical data such as age, BMI, smoking status, and diabetes mellitus (DM) status. Results: Both Dapagliflozin and Empagliflozin were associated with a numerical increase in mean Hct and Hb levels over a 3–6-month period. The increase in hemoglobin/hematocrit was statistically significant for the Empagliflozin group (p = 0.0107), but not for the Dapagliflozin group (p = 0.0642). There was no statistically significant difference in the magnitude of change in either Hct or Hb between the two drug classes. ANOVA revealed a significant difference in Hct change across different dose groups (p = 0.0327), with Dapagliflozin 10mg and Empagliflozin 25mg showing the largest increases. A significant negative correlation was found between baseline hematological parameters and their subsequent change, suggesting a greater effect in patients with lower baseline values.Conclusion: This analysis supports existing evidence that SGLT2 inhibitors increase hematocrit and hemoglobin. The effect on hematocrit is dose-dependent and slightly more noticeable with Empagliflozin. These findings add to the growing body of knowledge on the pleiotropic effects of SGLT2 inhibitors and highlight the need for further studies to elucidate the mechanisms underlying these hematological changes and their long-term clinical implications.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.